Robert Soiffer is an Oncology physician affiliated with Harvard University. OpenAlex indexes 1,155 publications with 44,634 citations (h-index 114); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
44 Binney St
Dana Farber Cancer Institute
Boston, MA 02115
Telephone
617-632-4731Registry record last updated 9 Jul 2007.
Clinical trials
- Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20255 payments$21,150openpaymentsdata.cms.gov ↗
- National Marrow Donor ProgramProgram year20259 payments
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.3%Kinase inhibitor24.4%Jakafi100%Part D≥17 patientsSelective immunosuppressants14.5%Rezurock100%Part D≥13 patients+ 1 more class in this area
Anti-infectives
22.4%Short-acting sulfonamides18.9%Sulfamethoxazole-Trimethoprim100%Part D≥17 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor3.5%Valacyclovir100%Part D<11 patientsDermatology
15.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.4%Acyclovir100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 1997–2023 per NIH RePORTER. The latest:
- Immune manipulation to generate tumor immunity and regulate GVHD after allogeneic HCT
Dana-Farber Cancer Inst
FY2023$604,938P01CA229092
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Cancer Immunology Research
2018 - Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
Journal of Clinical Oncology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”